The BMDI Cord Blood Bank (CBB) is one of three public cord blood banks in Australia and has more than 14,000 cord blood units (CBU) stored. More than 565 CBU have been released from the bank for treatment of patients with leukaemia and other blood disorders; cord blood (CB) remains an important donor source for bone marrow transplant. The CBB is licensed by the TGA and holds international accreditation through the Foundation for the Accreditation of Cellular Therapy (FACT). CB stored within the bank has met strict donor eligibility and quality requirements and has a high success of donor follow-up, even years’ post-donation. Banked CB therefore is an ideal source of well-characterised, GMP-grade starting material for clinical use beyond bone marrow transplant. Many studies, including our own, are exploring the use of CB for cellular therapies involving cardiac and neurological repair. CB is also being used to generate CAR-NK cells for treatment of leukaemia and virus-specific T-cells for immune recovery post-transplant. We have been exploring the use of banked CB as the ideal starting material to create GMP-grade induced pluripotent stem cell (iPSC) lines from donors with a homozygous haplotype (ie. ‘super-donors’). To this end we are able to generate stable iPSC lines from a tiny volume of stored CB under “GMP-like” conditions, free of animal products and feeder-cells. We have identified suitable CBU within the CBB and have obtained ethics approval to re-consent these donors to use their CB to create iPSC lines. In collaboration with the Global Alliance for iPSC therapies (GAiT) we have been developing the appropriate Quality Assurance parameters to ensure the safety and quality of the lines produced. Once manufactured, we believe this bank of clinical grade iPSCs will be an important source of stem cells to derive cells for therapeutic use.